FDA Finally Catches Up on COVID Drug Revocation
Published Date: 12/8/2025
Notice
Summary
The FDA has officially ended the emergency use of the drug Actemra (tocilizumab) for COVID-19 as of August 8, 2025. This change affects hospitals and patients who were using Actemra under emergency rules, meaning it’s no longer authorized for COVID-19 treatment. No new costs or payments are involved, but healthcare providers need to switch to other approved treatments.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Actemra Approved for Hospitalized Patients
On August 8, 2025, FDA approved a supplemental Biologics License Application expanding Actemra's approved indication to treat COVID-19 in hospitalized adult and pediatric patients aged 2 years and older who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Because this approved indication is an adequate alternative, FDA revoked the EUA for Actemra.
EUA for Actemra Revoked
The FDA revoked the Emergency Use Authorization (EUA) for Actemra (tocilizumab) for COVID-19 as of August 8, 2025. This means hospitals and patients using Actemra under the EUA can no longer use it under that emergency authorization and healthcare providers need to switch to other approved treatments; the notice states no new costs or payments are involved.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-22210 — 30-Day Notice of Proposed Information Collection: Application for Employment as a Locally Employed Staff or Family Member
The Department of State wants your thoughts on renewing the job application form for locals and family members applying to work at U.S. Embassies and Consulates worldwide. This form takes about 15 minutes to fill out, and around 600,000 people use it. You’ve got until January 7, 2026, to share your feedback—no money changes, just making sure the process stays smooth and clear!
Next: 2025-22212 — Notice of Public Hearing
The U.S. International Development Finance Corporation is hosting a virtual public hearing on December 12, 2025, to hear ideas and feedback from anyone interested. If you want to speak or send a written statement, you need to sign up by December 5. This is a great chance for stakeholders to influence decisions that could impact future investments and development projects.